SS-31 (Elamipretide) – Comprehensive Research Overview (2026)
SS-31 (Elamipretide, also known as MTP-131 or Bendavia) is a synthetic tetrapeptide that selectively targets the inner mitochondrial membrane. It is one of the most advanced mitochondria-targeted peptides in research, with a unique mechanism of action centered on cardiolipin stabilization. SS-31 is primarily researched for mitochondrial dysfunction, heart failure, renal protection, neurodegenerative diseases, and aging-related conditions. It has completed multiple Phase 2 clinical trials and holds FDA Breakthrough Therapy designation for heart failure with preserved ejection fraction (HFpEF).
→ View SS-31 (for laboratory research use only)
Chemical Structure and Properties
- Amino Acid Sequence: D-Arg-Dmt-Lys-Phe-NH₂ (Dmt = 2’,6’-dimethyltyrosine)
- Molecular Weight: ≈638 Da
- Form: Lyophilized powder for subcutaneous or intravenous injection
- Key Feature: Alternating cationic/aromatic residues enable selective accumulation in the inner mitochondrial membrane at cardiolipin-rich sites
Mechanism of Action
SS-31 selectively concentrates in the inner mitochondrial membrane and binds to cardiolipin:
- Stabilizes cardiolipin structure, preserving cristae architecture and electron transport chain (ETC) efficiency.
- Reduces mitochondrial reactive oxygen species (ROS) production without scavenging physiologic ROS.
- Restores ATP synthesis and mitochondrial membrane potential in stressed or aging cells.
- Reduces cytochrome c release and apoptotic signaling.
- Improves mitochondrial dynamics (fusion/fission balance).
Clinical Evidence and Research Findings
SS-31 has one of the strongest clinical pipelines of any research peptide:
- HFpEF (MMAD trial): Significant improvements in 6-minute walk distance and cardiac energetics.
- Renal protection: Reduced contrast-induced nephropathy and ischemia-reperfusion injury in trials.
- Mitochondrial myopathy: Improved exercise capacity and muscle function.
- FDA Breakthrough Therapy designation for HFpEF. Phase 3 trials ongoing.
→ Interested in researching SS-31? View Product Options
Benefits (Research & Clinical Observations)
- Improved mitochondrial efficiency and ATP production
- Reduced oxidative stress and mitochondrial ROS
- Cardioprotective and renoprotective effects
- Support for neurodegenerative disease models
- Potential anti-aging effects via mitochondrial restoration
Typical Dosing Protocols (Off-Label / Compounded)
- Clinical trial doses: 0.05–0.25 mg/kg IV or subcutaneous
- Off-label protocols: 5–20 mg subcutaneous daily or every other day
- Cycles: 4–12 weeks; effects may persist after treatment
Safety Profile and Side Effects
SS-31 has demonstrated a favorable safety profile across multiple clinical trials.
Common side effects:
- Mild injection-site reactions
- Transient nausea (rare)
Monitoring recommended: Cardiac and renal function markers with prolonged use.
SS-31 vs MOTS-c vs NAD+ – Quick Comparison
| Aspect | SS-31 | MOTS-c | NAD+ |
|---|---|---|---|
| Primary Target | Inner mitochondrial membrane | Mitochondrial genome / AMPK | NAD+ metabolism / sirtuins |
| Best For | Heart failure, renal protection | Metabolic syndrome, exercise | Cellular energy, longevity |
| Clinical Data | Phase 2/3 (Breakthrough Therapy) | Phase 1 safety confirmed | Moderate human data |
| FDA Status | Breakthrough Therapy (HFpEF) | Not approved | Supplement |
FAQ – Frequently Asked Questions
Is SS-31 FDA approved? Not yet. It holds FDA Breakthrough Therapy designation for HFpEF and is in Phase 3 trials.
How does SS-31 differ from antioxidants? SS-31 does not broadly scavenge ROS. It specifically stabilizes cardiolipin to restore mitochondrial efficiency, which is a more targeted and physiologic approach.
Can SS-31 be taken orally? No. It is administered by injection (subcutaneous or IV) due to poor oral bioavailability.
How long until results are seen? Improvements in exercise capacity and cardiac function have been observed within 4–8 weeks in clinical trials.
Summary
SS-31 (Elamipretide) is the most clinically advanced mitochondria-targeted peptide in research, with FDA Breakthrough Therapy designation and compelling Phase 2 data for heart failure, renal protection, and mitochondrial disease. Its unique cardiolipin-stabilizing mechanism offers a novel approach to restoring mitochondrial function in aging and disease. As with all compounds in this library, SS-31 is not yet an approved drug for general use and should only be considered under qualified medical supervision with appropriate monitoring.
For Laboratory Research Use View SS-31 →
Disclaimer This overview is strictly educational and based on publicly available scientific literature and regulatory information as of April 2026. It does not constitute medical advice, endorsement, or encouragement of use. Always consult a qualified healthcare professional and comply with all applicable laws and regulations.